Stock Ratings / Health Care / LKFT / options

SEPN (62) IMNM (38) XNCR (43) PVLA (46) ⌘ Pro Terminal →

Lakefront Biotherapeutics (LKFT) Options Positioning, Max Pain & Unusual Sweeps

$32.33 +0.78% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $32.31

Lakefront Biotherapeutics (LKFT) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $2.13B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $32.31 (-0.05%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 1.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LKFT)Realized 20D OHLCV Swing Band: ±5.3%

Deterministic 5-Pillar Attribution (61/100 Composite)

🔍 WHY LKFT SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (25% of score)

FRED Regime × Technicals: 63% of 52W Range • RSI-14 at 69.8 (BULLISH MOMENTUM)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$29.73+0.6% Next Q

Q2 (-2Q)

Grade C$29.90+5.9% Next Q

Q3 (-1Q)

Grade C$31.65+2.1% Next Q

Current

Grade C-$32.33+0.5% Hist 90D α

Trajectory: C- (53) → C- (61)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LKFT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 61/100 (C-) score, LKFT faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($29.49) or 200D SMA ($29.92) invalidates the momentum regime and cuts Target Base ($32.77) toward Bear Floor ($25.56).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LKFT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LKFT Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 61%NO 39%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±5.3%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (LKFT)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for LKFT.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating LKFT & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on LKFT
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LKFT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +16.17%▲ ASCENDING CHANNEL

2026-10-30O $32.42H $32.76L $32.06C $32.33VOL 164.1K

RES: $33.19SUP: $27.79SMA50: $29.49SMA200: $29.92

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LKFT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LKFT Butterfly Map → + Track LKFT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LKFT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LKFT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LKFT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LKFT)

Health Care Rank #182 of 1016 ⚔️ SEPN vs LKFT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LKFT vs. SEPN, IMNM, XNCR, PVLA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lakefront Biotherapeutics (LKFT) ranks #182 by composite RQD confidence (61/100, grade C-) and #252 by equity capitalization ($2.13B). Within this direct 5-issuer industry benchmark cohort, LKFT leads on earnings valuation at N/A trailing P/E, while SEPN leads on capital efficiency and profitability with -20.7% ROIC and — gross margin. SEPN currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with LKFT at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LKFT ACTIVE Lakefront Biotherapeutics	C-	61/100	—	—	—	+0.78%	$2.13B	Benchmark Subject
SEPN Septerna Inc.	C	62/100	—	—	-20.7%	+2.22%	$2.11B	/sepn-vs-lkft →
IMNM Immunome Inc.	D-	38/100	—	—	-35.0%	-2.50%	$2.16B	/imnm-vs-lkft →
XNCR Xencor Inc.	D-	43/100	—	—	-21.3%	-2.60%	$2.17B	/xncr-vs-lkft →
PVLA Palvella Therapeutics Inc.	D	46/100	—	—	-27.9%	+2.79%	$2.18B	/pvla-vs-lkft →

2. LKFT Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Lakefront Biotherapeutics (LKFT) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $2.13B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. LKFT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LKFT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Lakefront Biotherapeutics (NASDAQ: LKFT) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $32.33 (+0.78% 1D, market cap $2.13B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, LKFT ranks #182 in composite RQD confidence.

How does LKFT compare to SEPN and IMNM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LKFT carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SEPN (Septerna Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC -20.7%, cap $2.11B) and IMNM (Immunome Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $2.16B). Among the 5-stock peer group, LKFT leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LKFT?

For Lakefront Biotherapeutics (LKFT), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #182 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LKFT trading relative to its 50-day, 200-day, and 52-week technical levels?

LKFT last traded at $32.33 (+0.78% on volume of 245,970 shares), positioning the stock +9.63% above its 50-day simple moving average ($29.49) and +8.05% above its 200-day simple moving average ($29.92). Across its 52-week range of $25.68 to $36.24, LKFT sits at the 63.0% percentile with a 14-day RSI of 69.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.3% ($30.62 to $34.04).

LKFT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is LKFT's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for LKFT.

Direct Sub-Reports: LKFT RQD Cockpit LKFT 12M Forecast LKFT Earnings & Move LKFT Dividends & DRIP LKFT Insiders & 13F LKFT Whale Options LKFT Profit Sankey LKFT News & Why